middle.news
Percheron Therapeutics narrows FY2026 loss, advances HMBD-002 oncology drug with phase II trial planned
11:33am on Wednesday 19th of August, 2026 AEST
•
Biotechnology
Read Story
Percheron Therapeutics narrows FY2026 loss, advances HMBD-002 oncology drug with phase II trial planned
11:33am on Wednesday 19th of August, 2026 AEST
Key Points
68% reduction in annual loss to $4.79 million
HMBD-002 cleared phase I with strong safety profile
Phase II trial planned for second half of 2026
Cash reserves down to $4.05 million after $2.2 million equity raise
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE